Overview We are a developmental stage biopharmaceutical and cryptocurrency company. Our therapeutics focus is on developing novel therapeutics that address underserved conditions including PTSD, stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. We are focused on developing novel therapies that include conventional drugs and psychedelic formulations. The Companys lead program, SPC-15, is an intranasal drug targeting PTSD and stress-induced anxiety disorder...
Q2 FY2026 — expected 2026-09-14
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-27 | 2025-12-31 | 0001213900-26-035576 | EDGAR | 88K words |
| 2025-03-28 | 2024-12-31 | 0001013762-25-004139 | EDGAR | — |
| 2024-03-25 | 2023-12-31 | 0001213900-24-025615 | EDGAR | — |
| 2023-03-24 | 2022-12-31 | 0001213900-23-022813 | EDGAR | — |
| 2022-03-28 | 2021-12-31 | 0001213900-22-015521 | EDGAR | — |
| 2021-03-29 | 2020-12-31 | 0001213900-21-018270 | EDGAR | — |
| 2020-03-20 | 2019-12-31 | 0001213900-20-007000 | EDGAR | — |
| 2019-04-04 | 2018-12-31 | 0001213900-19-005789 | EDGAR | — |
| 2018-04-02 | 2017-12-31 | 0001213900-18-003903 | EDGAR | — |
| 2017-03-31 | 2016-12-31 | 0001213900-17-003182 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-13 | 2025-09-30 | 0001213900-25-110006 | EDGAR | 38K words |
| 2025-08-13 | 2025-06-30 | 0001213900-25-075693 | EDGAR | — |
| 2025-05-09 | 2025-03-31 | 0001213900-25-041519 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001213900-24-096841 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0001213900-24-068296 | EDGAR | — |
| 2024-05-13 | 2024-03-31 | 0001213900-24-042299 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0001213900-23-086214 | EDGAR | — |
| 2023-08-11 | 2023-06-30 | 0001213900-23-066300 | EDGAR | — |
| 2023-05-12 | 2023-03-31 | 0001213900-23-039078 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001213900-22-071252 | EDGAR | — |
| 2022-08-01 | 2022-06-30 | 0001213900-22-043390 | EDGAR | — |
| 2022-05-13 | 2022-03-31 | 0001213900-22-026450 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-02 | 0001213900-26-039352 | EDGAR | 3K words |
| 2026-02-23 | 0001213900-26-019384 | EDGAR | — |
| 2025-12-29 | 0001213900-25-125838 | EDGAR | — |
| 2025-10-24 | 0001213900-25-102222 | EDGAR | — |
| 2025-10-01 | 0001213900-25-094711 | EDGAR | — |
| 2025-08-05 | 0001213900-25-072062 | EDGAR | — |
| 2025-07-29 | 0001213900-25-068740 | EDGAR | — |
| 2025-07-10 | 0001213900-25-062805 | EDGAR | — |
| 2025-07-03 | 0001213900-25-061531 | EDGAR | — |
| 2025-05-16 | 0001213900-25-044913 | EDGAR | — |
175 total filings indexed. 143 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001514183 |
| Ticker | SILO |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | NV |
| Website | https://www.silopharma.com |
| Listed | 2012-01-05 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report